Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by ontheDLon Jul 28, 2011 12:34pm
323 Views
Post# 18883505

Is something good brewing?

Is something good brewing?

Is something good brewing? Golden Predator rallied after announcing initial drill results from the newly discovered Sleeman Zone at its Brewery Creek Project, the second major discovery on the company's project this year. Results of particular significance include the following: i) 191.5 m of 1.46 g/t gold beginning at a depth of 4.5 m in core hole BC11-226 (drilled subparallel to mineralized dike); ii) 40.3 m of 1.21 g/t gold beginning at a depth of 13.2 m in core hole BC11-229; and iii) 24.0 m of1.65 g/t gold from a depth of 62.5 m in core hole BC11-217. GPD says all holes reaching target depth encountered significant

mineralized intercepts of 24 m or more. The Sleeman Zone, located 2.5 km southeast of the previously announced Bohemian-Schooner Zone discovery, remains open in all directions. Given the success at Brewery Creek, GPD plans to further expand its2011 exploration budget: the company now looks to spend $7.5 million during the current fiscal year, an increase of $1.5 million following the tripling of the annual budget announced May 31, 2011. Drilling continues at Brewery Creek with two core rigs and one RC rig, and GPD is working to secure an additional rig in the coming weeks. Drilling is now being planned on a year-round basis, and the company is also establishing a permanent all-weather camp at Brewery Creek to augment existing facilities. GPD's Brewery Creek project is located in the Yukon.

 

*Canaccord Genuity and its affiliated companies may have a Corporate Finance or other relationship with the company and may trade in any of the Designated Investments mentioned herein either for their own account or the accounts of their customers, in good faith and in the normal course of market making. The authors have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance activities, or to coverage contained in the Morning Coffee.

Bullboard Posts